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chizophrenia is a devastating psychiatric disease
that has a lifetime prevalence of approximately 1%
worldwide. It is characterized by the occurrence of delu-
sions, hallucinations, disorganized speech, alterations in
drive and volition, impaired cognition, and mood symp-
toms.
1The importance of both environmental as well as
genetic factors in the development of this complex dis-
order has been demonstrated. Growing up in an urban
environment, immigration, cannabis usage, male gender
and perinatal events (hypoxia, maternal infection, stress,
and malnutrition) are associated with increased risk of
developing schizophrenia.
1,2 Evidence from family, twin,
and adoption studies suggests a strong genetic compo-
nent. A meta-analysis of twin studies estimated the her-
itability to be 81% (confidence interval 73% to 90%)
3
and a recent Swedish study of more than 2 million fami-
lies estimated it to be 64%.
4 Of all the known risk factors
for schizophrenia, genetics is the single largest one. No
precise mode of inheritance is known, and less than one
third of patients with schizophrenia have a family history.
Elucidation of etiological factors remains the over-
whelming challenge to schizophrenia researchers. In fact,
the most effective method for identification of genetic
risk factors for schizophrenia is not clear, and this has led
to a number of approaches, including epigenetics, being
adopted, in an attempt to clarify the genetic etiology.
Since the initial observation that schizophrenia has a
polygenic mode of inheritance and availability of poly-
morphic markers for genetic mapping, many attempts
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Understanding the genetic basis of schizophrenia con-
tinues to be major challenge. The research done during
the last two decades has provided several candidate
genes which unfortunately have not been consistently
replicated across or within a population. The recent
genome-wide association studies (GWAS) and copy num-
ber variation (CNV) studies have provided important evi-
dence suggesting a role of both common and rare large
CNVs in schizophrenia genesis. The burden of rare copy
number variations appears to be increased in schizo-
phrenia patients. A consistent observation among the
GWAS studies is the association with schizophrenia of
genetic markers in the major histocompatibility complex
(6p22.1)-containing genes including NOTCH4 and his-
tone protein loci. Molecular genetic studies are also
demonstrating that there is more overlap between the
susceptibility genes for schizophrenia and bipolar disor-
der than previously suspected. In this review we sum-
marize the major findings of the past decade and sug-
gest areas of future research.  
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PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 289have been made to find susceptibility genes for schizo-
phrenia using either the methods of linkage or associa-
tion.
5,6
One of the early strategies used to begin unraveling the
genetic contribution of schizophrenia was the investiga-
tion of chromosomal aberrations and familial syndromes
with schizophrenia-like phenotypes. Chromosomal aber-
rations have been reported in families with schizophre-
nia and other psychiatric disorders.
7,8 The deletion of a
section of 22q11 leads to the phenotype of velocardio-
facial (DiGeorge) syndrome that includes abnormalities
in facial features, the palate, and midline heart defects.
Patients with 22q11 deletion syndrome exhibit psychotic
symptoms resembling schizophrenia at a frequency of
18%, a rate that is much higher than the overall 1%
prevalence of schizophrenia in the general population.
On the other hand, when focusing on populations of
patients who have the diagnosis of schizophrenia, at least
2% of these individuals are reported to have 22q11 dele-
tions compared with the 0.025% prevalence in the gen-
eral population.
9,10 This region of 22q11 harbours the
COMT and PRODH genes among others (Table I). 
A number of other chromosomal aberrations have
been associated with schizophrenia. On chromosome
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Gene Locus Function Rare event
a Animal model
b Expression
c Meta-analysis
d References
AKT1 14q22-32 Intracellular signaling ND ↓ - 11,12
APOE 19q13.2 Synapses ND ↑ + 12,13
COMT 22q11 Catecholamine + -
MB ↔ ++ 12,14,15-19
metabolism
DAOA(G72) 13q32-34 D-serine metabolism PPI def ↑ ++ 12,20,21
DISC1 1q42 Neurodevelopment and  + PPI/LI def ↔; FEZ↓; NUDEL↓; LIS1↓ +++ 12,22-27
synaptic function
DRD2 11q23 Dopamine signaling ND ↓ ++ 12,28
DTNBP1 6p22 Neurodevelopment and  PPI def ↓ +++++ 29-31
synaptic transmission
ERBB4 2q33.3-q34 Receptor tyrosine kinase NRG1 + PPI def ↔/↑ ND 32,33-35
GABRB2 5q34 GABA signaling ND ↓ ++++ 12,37
GRIN2B 12p12 Glutamate signaling ND ↔ ++ 12,38,39
HTR2A 13q14-21 Serotonin signaling ND
HIP↓ - 12,24,40
IL1B 2q14 Immune ND
CSF↑ + 41-43
NOTCH4 6p21.3 Neurodevelopment ND +++ 12,34,35,44-46
NRG1 8p12-21 Synapses PPI/LI def ↑ Haplotype 47
NRXN1 2p16.3 Synapses + PPI def ND ND 44-46
PDE4B 1p31 Synapses PPI def ↓ ND 48-51
PRODH 22q11 Glutamate synthesis + PPI def ↔ - 12,15,18,19
RELN 7q22 Synapses NPAS1/3 def: PPI def ↓/↔ ND 23,52,53
RGS4 1q23 Regulator of G-protein signaling - ↓ - 12,54,55
Table I. Some schizophrenia candidate genes and their association with schizophrenia according to chromosomal location, genetic association, biol-
ogy/animal models, expression alterations, and meta-analysis results. The number of ”+” indicates the strength of association. “ND” not deter-
mined (modified from ref 126). 
a Rare events include chromosomal abnormalities, copy-number variants, mutations that have been associated
with schizophrenia. 
b Data on genetically modified mouse models; PPI = prepulse inhibition in rodents; “-“ = PPI similar to wildtype. 
c Expression
data on postmortem tissues from the frontal/prefrontal cortex unless specified; MB = membrane-bound isoform; CSF = cerebrospinal fluid;
HIP = hippocamupus.
d Results from most recent meta-analyses: #”+” = #significant polymorphisms; most updated meta-analysis of case-con-
trol studies is available SZGene (www.schizophreniaforum.org). AKT1, v-akt murine thymoma viral oncogene homolog 1; APOE, Apolipoprotein
E; COMT, Catechol-O-methyltransferase; DAOA(G72), D-amino acid oxidase activator; DISC1, Disrupted in schizophrenia 1; DRD2, Dopamine
receptor 2; DTNBP1, Dystrobrevin binding protein 1; ERBB4, v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian); GABRB2,
Gamma-aminobutyric acid (GABA) A receptor, beta 2; GRIN2B, Glutamate receptor, ionotropic, N-methyl D-aspartate 2B; HTR2A, 5-hydrox-
ytryptamine (serotonin) receptor 2A; IL1B, Interleukin-1 beta; NOTCH4, Notch homolog 4 (Drosophila); NRG1, Neuregulin 1; NRXN1, Neurexin
1; PDE4B, Phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila); PRODH, Proline dehydrogenase (oxidase)
1; RELN, Reelin; RGS4, Regulator of G-protein signaling 4
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disrupted the DISC1 gene (Table I), was found in a
large Scottish family with high frequency of psychiatric
disorders including schizophrenia.
22,56,57 More recently,
another family of mother-daughter pair with schizo-
phrenia was identified with t(9;14)(q34;q13) transloca-
tion which disrupts the NPAS3 (neuronal Period Aryl
hydrocarbon receptor Single-minded) gene,
58,59 that
codes for a transcription factor implicated in neuroge-
nesis. Another cytogenetic investigation of a patient
with schizophrenia revealed complex chromosomal
rearrangement involving regions containing FEZ1
(which interacts with DISC1) and the kainate gluta-
mate receptor gene GRIK4.
60 The gene coding for
another DISC1 interacting protein, PDE4B, was found
to be disrupted by a translocation in a schizophrenia
proband with family history of psychiatric disorders.
61
In these studies, however, the chromosomal aberrations
do not fully cosegregate with the SCZ phenotype; thus
these chromosomal abnormalities alone are not suffi-
cient to cause SCZ, and they may predispose to several
major psychiatric disorders as observed in some of
these families, including bipolar disorder, major recur-
rent depression, addictions, impulse control disorders,
and others.
Linkage studies are family based analyses that utilize
genetic markers and the information from multiple
affected individuals present in a given family to identify
linked regions of the genome that is, regions coinherited
or segregating with the disease. Linkage studies were ini-
tially carried out using highly informative microsatellite
markers (approximately 400 markers to cover the
genome). At present, pedigree studies can utilize single-
nucleotide polymorphism (SNP) linkage marker sets (eg,
6056 SNPs set from Illumina Inc). Some interesting can-
didate genes have been identified from linkage scans
and have been replicated in independent association
studies. These include dystrobrevin binding protein 1
(dysbindin, DTNBP1, 6p22.3),
62 neuregulin 1 (NRG1,
8p12),
32 and D-amino acid oxidase activator (DAOA,
13q24).
63A recent meta-analysis of 32 genome-wide link-
age scans across 3255 pedigrees including 7413 affected
individuals identified suggestive evidence of linkage
based on the summed rank statistics (PSR<0.0077) in two
regions: 5q (5q31.3-35.1; PSR=0.0046 ) and 2q (2q12.1-
21.2;  PSR=0.0075).
64 Following secondary analysis,
genome wide evidence of linkage was observed on 2q
(PSR=0.00035) after shifting the frame of the 30 centi-
morgan wide bins by 50%. The next most significant
regions, in descending order were: 1p13.2-q23.3, 2q33.3-
36.3, 2q21.2-31.1, 1p32.2-31.1, 5q35.1-35.3, 8p22-12,
10q26.12-26.3, and 3p14.1-q13.32. Suggestive evidence of
linkage with the 8p region (8p22-12, 16-33Mb;
PSR=0.00057) was also observed in the subsample of
patients of European ancestry. The 2q, 5q, and 8p regions
were found to be linked to schizophrenia in an earlier
meta-analysis from a subgroup of 20 studies from this
larger set.
65 Furthermore, Holmans et al
66 reported sug-
gestive evidence of linkage with 8p21 in a subset of the
above families of European ancestry (707 families, 1615
affected). Since this 8p21 region does not include the
gene NRG1, they concluded that this linkage might be
due to the presence of one or more loci with multiple
rare risk-associated SNPs and/or structural variants. The
utility of linkage studies was further demonstrated in a
recent study where the protein kinase C alpha
(PRKCA) gene was identified as a schizophrenia sus-
ceptibility site. Carroll et al
67 examined a linkage area
that they had identified earlier on chromosome 17p11.2-
q25.125 and they identified a rare four-marker haplotype
in the 3’ untranslated region of the PRKCA gene. They
further demonstrated that this low-frequency haplotype
showed a trend of association in a sample of unrelated
schizophrenia cases and controls (661 cases, 2824 con-
trols, P=0.078, OR=1.9) and was significant in a pooled
sample of schizophrenia, schizoaffective, and bipolar dis-
order patients (P=0.037, OR=1.9). This association was
more significant in a stratified sample of males with
schizophrenia than in the pooled sample. However, this
association was not replicated in independent samples
from Ireland and Bulgaria. Caroll et al
67 also reported
that common SNPs in the linkage region showed asso-
ciation with schizophrenia in a United Kingdom sample,
although these SNPs did not replicate across other sam-
ples. A possible interpretation of this scenario is that
both common and rare SNPs in the PRKCA gene region
may be associated with schizophrenia and related disor-
ders. 
Although some interesting candidate genes have been
identified using linkage methods, a major criticism of
these studies is that linkage signals are observed on most
of the chromosomes and cover thousands of genes.
Furthermore, small effect sizes that are now expected for
schizophrenia-associated polymorphisms (OR<1.2) and
locus heterogeneity further reduces the chances of find-
ing a truly significant region in linkage studies. In addi-
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ple affected individuals for detecting these small effect
sizes is labor-intensive and expensive. However, in con-
trast to genome-wide association studies (GWAS), large-
scale linkage studies have the advantageous ability to
detect regions with multiple rare as well as common
variants (allelic heterogeneity) in one or more suscepti-
bility genes.
64,65,68 Furthermore, focusing on families with
multiple affected individuals likely enriches for trans-
mitted genetic factors and reduces etiologic hetero-
geneity. 
Candidate gene and genome-wide 
association studies 
The limited power of linkage studies to identify genes of
modest effect led Risch and Merikangas
69 to propose the
usage of association studies for disease gene identifica-
tion in disorders with complex architecture such as schiz-
ophrenia. The primary advantage of the latter strategy
was the possibility to recruit a large sample size with
enough power to detect loci of moderate effect.
However, they recognized that an important limitation
was the lack of availability of technology to assay a large
number of polymorphisms across the genome (up to 100
000). This limitation was overcome by the development
of prototype SNP chips containing initially only 500
SNPs,
70 however ,progressing rapidly to the present-day
commercially available chips containing over a million
SNPs.
71 Furthermore, the cost of these chips has come
down dramatically over the last few years, making it pos-
sible to carry out high-throughput genotyping in very
large populations (over 20 000 individuals). The com-
pletion of the human genome project,
72 the parallel
development of the HapMap database of human SNP
variation, and the availability of information on more
than 3.1 million SNPs across the human genome have
paved the way to effectively carry out large-scale
GWAS.
73-75
Genetic association studies are based on the common
disease common variant hypothesis. This hypothesis pro-
poses that common diseases are a result of interactive
contribution of common variants with small effect sizes,
and the susceptibility alleles will be shared by a signifi-
cant proportion of unrelated affected individuals. This is
the basis of both hypothesis-based candidate gene asso-
ciation studies as well as the hypothesis-free GWAS
method.
In the past 4 years at least 11 GWAS have attempted to
identify susceptibility genes for schizophrenia by geno-
typing individual samples as well as using DNA pooling-
based methods.
GWAS using DNA pooling 
DNA pooling was initially proposed as a method to
reduce genotyping costs in large-scale association stud-
ies.
76 DNA from cases and controls are pooled into two
separate groups, and the differences in allele frequency
between the two groups are estimated to assess associa-
tion. The first pooling-based association study was gene-
centric, and analyzed 25 494 SNPs present within 10 kb
of each of a large set of genes
77 (Table II). In the initial
discovery sample a significant association of the marker
rs752016 in intron 11 of the Plexin A2 gene (PLXNA2,
1q32; OR = 1.49; P=0.006) was found. A similar associa-
tion was observed in the replication case-control as well
as family based samples. However, independent replica-
tions for this SNP have been mixed.
78-80
Shifman et al
81 conducted a pooling-based GWAS study
and observed female-specific association of the SNP
rs7341475 G/A, in the fourth intron of the reelin gene
(RELN, ORGG=2.1, 9.8x10
-5). This was confirmed in a
replication sample of patients of European ancestry
from the United Kingdom, but not in samples from
three other populations (Irish, American, and Chinese).
The trend in the last three samples was in the same
direction, and was significant in a meta-analysis includ-
ing all samples ORGG=1.58 (1.31-1.89), P=8.8x10
-7.
However none of these observations were significant
after correcting for multiple testing. The reelin protein
is a serine protease that plays an important role in cor-
ticogenesis and it is associated with an autosomal reces-
sive form of lissencephaly.
82 It has also been implicated
in neurotransmitter-related GSK3β signaling and regu-
lation of NMDA receptor activation.
83 Polymorphisms in
the RELN gene have been associated with neurocogni-
tive endophenotypes of schizophrenia (eg, working
memory and executive functioning).
84,85 Furthermore, the
association of the RELN gene with schizophrenia has
been replicated in an independent sample.
86
In a whole genome pooling-based study on patients of
eastern European ancestry (Bulgaria) significant associ-
ation of rs11064768 in intron 1 of coiled-coiled domain
containing protein 60 (CCDC60, 12q24.23) was observed.
87
The second best SNP was rs11782269 that is present in an
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23 (CLDN23). The third best was rs893703 in the intron
2 of retinol binding protein 1 gene (RBP1, 3q23).
Interestingly, the RBP1 gene has been implicated in schiz-
ophrenia pathogenesis and inhibits PI3K/Akt signaling.
However these observations are not significant at the
genome-wide significance level (P=1.85X10
-7) and have
not been investigated in other independent samples. In
general, the genetic findings support the neurodevelop-
ment hypothesis of schizophrenia.
88
GWAS with individual genotyping
In the first GWAS, Lencz et al
99 observed genome-wide
significant association of a SNP rs4129148 near the
colony stimulating factor 2 receptor alpha gene
(CSF2RA) in the pseudoautosomal region (Table II).
Homozygosity for the C-allele of this polymorphism was
associated with over threefold increased risk for schizo-
phrenia. They targeted the exonic sequences and
upstream region of CSFR2A and its immediate neigh-
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Study no Ethnicity Sample size No of SNPs  Significant SNPs  Gene
tested (P-value)
Discovery Replication
(cases/ controls) (cases/ controls)
1 Mah et al, 2006
77 European ancestry 320/325 200/230
c 25 494 rs752016 (0.006) PLXNA2
2 Lencz et al, 2007
89 European ancestry 178/144 71/31
a 439 511 rs4129148 (3.7X10
-7) CSF2RA
and IL3RA
3 Sullivan et al, 2008
92 European/African 738/733 -- 492  900 -- --
ancestry/ others
4 O’Donovan et al, 2008
93 European 479 /2937 6,666/9897
b 362 532 rs1344706 (1.95x10
-7) ZNF804A
5 Shifman et al, 2008
81 Ashkenazi Jews 241/964
d 768/2194
d rs7341475 (2.9X10
-5)
d RELN
6 Kirov et al, 2009
87 European ancestry 574 Trios/605 -- 433 680 rs11064768(1.2X10
-6) CCDC60
rs11782269 (8.4X10
-5) 8p23.1
rs893703 (1.6X10
-4) RBP1
7 Need et al, 2009
98 European ancestry 871/1460 863/12 995 312 565 rs2135551 (1.34X10
-6) ADAMTSL3
8 Internation  European ancestry 3322/3587 8008 /19 077 739 995 rs13194053 (9.5X10
-9) 6p22.1
Schizophrenia  (ISC, MGS & SGENE rs5761163 (3.4X10
-7) MYO18B
Consortium
96 combined) rs3130297 (4.79X10
-8) NOTCH4
rs3130375 (3.66X10
-7) RPP21
9 Stefansson et al,  European ancestry 2663/13 498 4999/15 555 314 868 rs6913660 (1.1X10
-9) HIST1H2BJ
2009 (SGENE-plus)
41 rs6932590 (1.4X10
-12) PRSS16
rs13211507 (8.3X10
-11) PGDB1
rs3131296 (2.33X10
-10) NOTCH4
rs12807809 (2.4X10
-9) NRGN
rs9960767 (4.1X10
-9) TCF4
10 Shi et al, 2009 European and 3967/3626 8008 /19 077 696 788 in EA 6p22.1 HIST1H2BJ,
(MGS)
109 African ancestry (ISC, MGS & 843 798 in AA 1.06-4.35X10
-8 HIST1H2AG,
SGENE HIST1H2BK,
combined) HIST1H4I and
HIST1H2AH
11 Athanasiu et al, 2010
100 European ancestry 201/305 2666/13 780 572 888 rs7045881 (2.12X10
-6)  PLAA
rs433598 (3.27X10
-6)  ACSM1
rs10761482 (3.27X10
-6) ANK3
Table II. A Summary of whole-genome association studies in schizophrenia. 
aThis sample was used for sequencing the genes identified close to the
SNP rs4129148 (CSF2RA and IL3RA). 
bThe replication sample included individuals from Japan and China. 
cAn independent case-control repli-
cation sample included patients of African descent (cases/controls; 157/180), Latin Americans (111/123) and Asian Americans (63/72). Two
family-based samples (294 affected sib pair nuclear families and 90 affected sib pairs and 6 multiplex families). 
dFemales only. Ethnicity refers
to the ancestry of only the Discovery sample set. EA, European ancestry; AA, African ancestry
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sequencing in an independent patient sample (n=102).
They observed that intronic haplotype blocks within
CSF2RA and IL3RA were significantly associated with
SCZ. Interestingly, one polymorphism, rs6603272, in
intron 5 of the IL3RA gene, was also found to be asso-
ciated with schizophrenia in independent samples of
Han Chinese patients.
90,91 Lencz et al
89 also observed an
excess of rare non-synonymous mutations in CSF2RA
and IL3RA in schizophrenia patients. No further stud-
ies of these two genes in schizophrenia have been
reported since the findings of Lencz et al in 2007. There
may be a tendency to be noted here, that each new
GWAS study highlights the top ranking markers that it
finds, and does not pay much attention to previously
reported findings. This tendency is compounded by the
fact that there is an explosion of data available to
GWAS investigators; thus, putative new associations are
arising in large numbers, providing a wide array of leads
to follow. 
In the GWAS on schizophrenia subjects from the
Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study (n=1471), no marker
achieved genome-wide significance level.
92 A possible
reason for this was the inclusion of patients of diverse
ancestry who were not adequately covered in the geno-
typing platform that the investigators had utilized. The
genomic coverage for common SNP variation was 86%
for subjects of European ancestry, 79% for East Asian
ancestry and only 49% for African ancestry (with
r
2≥0.8).
92
One of the most interesting candidate genes for schizo-
phrenia and psychosis came from the multistage GWAS
analyzing over 20 000 cases and controls.
93 In the initial
GWAS (479 cases, 2937 controls), O’Donovan et al
93
observed 12 loci to be moderately associated with schiz-
ophrenia (P<10
-5). In the first replication sample (1664
cases, 3541 controls) association of 6 of the 12 SNPs was
replicated. These six SNPs were genotyped in the second
replication sample (4143 cases, 6515 controls). In the com-
plete replication sample set (stage one + two), three loci
namely: Zinc finger protein 804A (ZNF804A, rs1344706,
2q32.1,  P=9.25x10
-5), intergenic regions on 11p14.1
(rs1602565,  P=3.22x10
-4) and 16p13.12 (rs7192086,
P=5.10x10
-4) were modestly associated with schizophre-
nia. In the combined sample from the initial stage plus the
two replication sets, ZNF804A showed strong evidence of
association (OR=1.12; P=1.6x10
-7). Furthermore, when
patients with bipolar disorder were included, the obser-
vation became more significant, suggesting that ZNF804A
might be a susceptibility gene for the broader psychosis
phenotype. ZNF804A is a putative transcription factor
and the risk allele of the rs1344706 polymorphism (intron
2, C>A) has been recently shown to be associated with
disturbed connectivity between the dorsolateral pre-
frontal cortex (DLPFC) and the hippocampus, as well as
between left and right hemispheres. Also there was
altered coupling of DLPFC with the amygdala.
94The for-
mer may lead to disturbed executive function and the lat-
ter can affect the interaction between prefrontal and lim-
bic structures. The association of ZNF804A marker
rs1344706 with schizophrenia was recently replicated in
patients from Ireland (n=1021 cases, 626 controls;
P=0.01).
95 Increased expression of the A allele compared
with the C allele was observed in the dorsolateral pre-
frontal cortex of postmortem control brain samples.
However, there was no difference between the two alle-
les in overall mRNA expression between postmortem
schizophrenia cases and controls.
94 The SNP rs1344706
was also significant in the GWAS conducted by the
International Schizophrenia Consortium (P=0.029, OR
(A-allele) =1.08).
96 Additionally, in a large multicenter
study, association of rs1344706 with schizophrenia (5164
cases and 20 709 controls; OR=1.08, P=0.0029) and psy-
chosis (OR=1.09, P=0.00065) has been replicated.
97 Based
on this replication by three other independent groups, and
the demonstration of functional effect on brain connec-
tivity, ZNF804A is a promising candidate gene for schiz-
ophrenia and psychosis in general. The small effect sizes
(OR 1.08-1.12) account for only 1% to 2% of the variance
in risk for the disease. In general these replicating small
effects are consistent with the common disease common
variant hypothesis.
In the GWAS conducted by Need et al
98 no SNP reached
the genome-wide significance level; however the
strongest association was observed for a SNP in the 3’-
UTR of ADAMTS-Like protein 3 (ADAMTSL3,
rs2135551, P=1.35x10-7, OR=0.68). An effect on splicing
was demonstrated for the SNP rs950169 which is in link-
age disequilibrium with rs2135551. The genetic associa-
tion of rs2135551 was replicated in an independent
cohort of patients but was not replicated in three other
sample sets. Need et al also analyzed whether associa-
tion of other current candidate genes for schizophrenia
was present in their study. They observed gene-wide
association of polymorphisms in Fasciculation and elon-
Translational research
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(NOTCH4). 
By the middle of 2009, three GWAS of impressive scale
were conducted by three large consortia for schizophre-
nia genetics. Each effort examined several thousand cases
and controls, and they were published in the same issue
of Nature. The study from the International Schizophrenia
Consortium (ISC) analyzed 3322 schizophrenia cases and
3587 controls.
96 The most significant association was
observed for rs5761163 in the first intron of myosin XVI-
IIB (MYO18B; 22q11.2-q12.1; P=3.4x10
-7). The second
strongest association was with SNPs spanning the major
histocompatibility complex (MHC, 6p22.1) and the most
significant SNP was rs3130375. Following imputation,
rs3130297, located in the MHC region 7.1 kilobases (kb)
upstream from the Notch homolog 4 gene (NOTCH4)
showed genome-wide significance (P=4.79x10
-8). A trend
for association of this SNP was observed in the Molecular
Genetics of Schizophrenia (MGS) sample (P=0.086)
99 but
not in the SGENE sample (P=0.14).
41 In the combined
sample from the three studies, including both imputed and
genotyped SNPs in the MHC region, rs13194053 was
genome-wide significant. The study also provided evi-
dence that a large number of common variants have an
important role to play in schizophrenia susceptibility, as a
group explaining about one third of the total variation in
risk for the disease (34% [CI=32%-36%]).
96
In the second GWAS, performed by the SGENE con-
sortium, Stefansson et al
41 did not observe any genome-
wide significant SNPs in their sample of 2663 schizo-
phrenia cases and 13 498 controls. They analyzed the top
1500 SNPs in the ISC (2602 cases and 2885 controls) and
the MGS samples (2681 cases and 2653 controls). The
top 25 markers (P<1x10
-5) in the combined sample were
followed up in four independent samples (total of 4999
cases and 15 555 controls). They observed genome-wide
significant association of SNPs in the MHC region
(6p21.3-22.1, HIST1H2BJ, PRSS16, and NOTCH4), as
well as with the marker rs12807809 located 3.4kb
upstream of the neurogranin gene (NRGN, 11q24.2),
and an intron four SNP in transcription factor 4 (TCF4,
18q21.2). The odds ratios for associated SNPs in the
MHC region varied from 1.15 (HIST1H2BJ, rs6913660,
P=1.1x10
-9), to 1.19 (NOTCH4, rs3131296, P=2.3x10
-10)
to 1.24 (PGDB1, rs13211507, P=8.3x10
-7). The genes
associated in this study are involved in immune-related
functions (MHC), impaired memory function (NRGN),
and neurodevelopment (TCF4).
41
The Molecular Genetics of Schizophrenia (MGS) study
99
was not able to identify genome-wide significant mark-
ers in their sample set. The MGS study had both
African-American (AA, 1 286 cases, 973 controls) as
well as European ancestry (EA) patients (2681 cases,
2653 controls). In the EA sample the top SNP was an
intron 10 polymorphism rs13025591 in the AGAP1 gene
(ArfGAP with GTPase domain, ankyrin repeat and PH
domain 1, 2q37.2, P=4.6x10
-7, OR=1.22). Among the top
SNPs were an intron 12 SNP, rs16941261, in NTRK3
(neurotrophic tyrosine kinase, receptor, type 3, 15q25.3,
P=8.1x10
-7, OR=1.25) and intron two SNP, rs10140896,
in EML5 (echinoderm microtubule associated protein-
like 5, 14q13.3, P=9.5x10
-7, OR=1.22). In the African-
American subsample, ERBB4 (v-erb-a erythroblastic
leukemia viral oncogene homolog 4, 2q34, rs1851196,
P=2.4x10
-6, OR=0.733) and CBX2 (chromobox homolog
2, 17q25.3, rs3751954, P=4.6x10
-6, OR=0.528) were asso-
ciated. ERBB4 and its ligand neuregulin 1 (NRG1) have
been associated with schizophrenia in earlier studies (for
discussion see http://www.schizophreniaforum.org).
NRG1 is a very large gene that presents challenges for
more detailed study due to its size. Certain areas of the
gene have been highlighted by the fact that haplotypes
of markers in these regions have exhibited some repli-
cation across schizophrenia studies. However, the lack
of detailed information as to which markers in the gene
alter its biological function leads to a need to cover the
entire gene with a set of hundreds of markers, in order
to be able to state that a comprehensive analysis was
done. Thus, even in this single locus, one can see that
multiple testing challenges arise. Overall, it can be seen
that much more work by genome researchers on anno-
tation of the functional significance of variants in any
given gene is required.
Shi et al
99 further conducted a meta-analysis of the sam-
ples of European ancestry in their MGS sample as well
as samples from ISC and SGENE (total sample: 8008
cases, 19 077 controls). Genome-wide significant associ-
ation was observed with SNPs on chromosome 6p22.1
spanning 209kb. The strongest association was with the
SNPs present within a cluster of five histone genes
(HIST1H2BJ, HIST1H2AG, HIST1H2BK, HIST1H4I,
and HIST1H2AH). The surrounding region also includes
genes related to immunity, chromatin modification and
G protein-coupled receptor signaling.
To summarize across these large GWAS investigations,
each group of authors did not find genome-wide signif-
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ally. They found significant results only when they
merged samples from several large studies and con-
ducted pooled analysis. The overall finding was the asso-
ciation of SNPs in the MHC region (6p22.1) with schiz-
ophrenia. These results provide strong evidence that
common variants are associated with schizophrenia;
however, the effect size of the risk variants is small
(<1.2). Therefore, studies with small sample size are
unlikely to detect these common variants, unless these
SNPs have larger effect size in more refined phenotypes. 
In a recent GWAS on a Norwegian sample, Athanasiu
et al
100 also failed to find genome-wide significant results
in their discovery sample (n=506), probably due to the
small sample size. However, when they analyzed the top
1000 SNPs of their study (or the surrogates of these
SNPs) in the SGENE-plus consortia sample,
41 16 loci
showed marginal association (P<0.05). In the combined
analysis they observed three markers to be significant at
the genome-wide level. These were- rs7045881 in the
gene phospholipase A2-activating protein (PLAA, 9p21,
P=2.12x10
-6, OR=0.86); rs433598 in acyl-CoA synthetase
medium-chain family member 1 (ACSM1, 16p12.3,
P=3.27x10
-6, OR=1.13); and rs10761482 in ankyrin 3,
node of Ranvier (ankyrin G) gene (ANK3, 10q21,
P=3.27x10
-6, OR=0.86). The function of these genes
includes inflammatory response and membrane integrity
(PLAA), endocrine function and dislipidemia (ACSM1),
and involvement in activities such as cell motility, acti-
vation, proliferation, contact, and maintenance of spe-
cialized membrane domains (ANK3). Interestingly
ANK3 has also been associated with bipolar disorder in
a recent meta-analysis.
101 In addition to the above obser-
vations, Schulze et al
102 also observed nominal associa-
tion of genes for bipolar disorder that have been associ-
ated with schizophrenia in candidate gene as well as
genome-wide association studies (DISC1,  NRG1,
RELN, and OPCML).
One of the major new observations from the GWAS
studies is the fact that many of the positive loci for schiz-
ophrenia are also positive in bipolar, and vice-versa. This
molecular-genetic overlap may have important implica-
tions for diagnostic classification of schizophrenia in the
future DSM-5 and beyond. Also in the future, the field
will see a transition from SNP methodology to DNA
sequencing. Thus all of the DNA variation in a given
gene will be detected. For example, the sequencing will
detect small insertions and deletions, as well as repeat
sequences, that largely would have been missed by the
current SNP arrays. The downside of this large increase
in the amount of information available will be even
more multiple testing challenges, as well as considerable
labor to establish the functional status of each variant of
the gene in question. 
Copy number variation and schizophrenia
Considering that two thirds of the cases of schizophre-
nia are sporadic, a role of rare variation in development
of schizophrenia is not unexpected. Rare variations can
include mutations as well as deletions and duplications.
Copy number variations (CNV) are submicroscopic
deletions or duplications stretching from a few kilobases
to several megabases covering several or many genes.
One of the earliest well-supported deletions relating to
schizophrenia is on 22q11. This region, also known as the
velocardiofacial/DiGeorge (VCFS) syndrome region, is
caused by a deletion of 1.5 to 3Mb on one chromosome
(thus rendering the person hemizygous for the genes
involved). Besides the features observed in patients with
VCFS, the 22q11 deletion region is associated with
increased risk of schizophrenia and other neuropsychi-
atric disorders.
14
Initial studies of CNVs in schizophrenia were carried out
using bacterial artificial chromosome (BAC) array com-
parative genome hybridization (aCGH) with the reso-
lution ranging from 2.3 Mb,
102 1.4 Mb,
103 0.7 Mb,
104 to 150
-200kb.
105 The more recent studies have utilized SNP
arrays for estimation of CNVs with a resolution of
approximately 30 to 100kb.
98,106-110
Using array CGH, several regions harboring deletions
and duplications were identified in Korean schizophre-
nia patients.
102Two frequent CNVs were observed. First
was a gain in sequence that varies in length across indi-
viduals in the Xq23 region (in 52% of schizophrenia
cases). Second, was a loss at 3q13.12 (in 32% of schizo-
phrenia cases). They also identified deletion as well as
duplications at 22q11.21. Wilson et al
103 analysed 105
postmortem brain samples, n=35 each for schizophrenia,
bipolar disorder and controls and observed CNVs at
1p34.3 (GLUR7), 5q21.3 (EFNA5), 14q23.3 (AKAP5),
and 22q12.3 (including the CACNG2 gene) in cases but
not in controls. Furthermore, three of the CNV loci,
except for 5q12.3, were replicated in an independent
sample of 60 psychiatric patients.
103 Similarly, Mizuguchi
et al also observed CNVs in six (10%) of the 59 schizo-
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centage of SCZ patients with one of a set of common
deletions continues to be observed, then genetic screen-
ing for these deletions may become more useful, as dis-
cussed recently for 22q11.2 deletions.
111
The study by Kirov et al
105 detected 13 CNVs in 93 schiz-
ophrenia patients. These were not detected in 372 con-
trol individuals. Of these CNVs two were thought to
have a possible role in schizophrenia pathogenesis. The
first was a 1.4 Mb de novo duplication on chromosome
15q13.1 which includes the gene amyloid β (A4) pre-
cursor protein binding, family A, member 2 (APBA2),
and the second was a 0.25Mb deletion on 2p16.3 that
includes the Neurexin gene (NRXN1). Gene-gene inter-
action between APBA2 and NRXN1 is known and both
play a role in synaptic development and function.
105
An excess of rare CNVs (both deletion and duplica-
tions) in schizophrenia and schizoaffective disorder
patients (20%) versus controls (5%) was reported by
Walsh et al.
112 Similar excess of rare CNVs was observed
in young-onset cases (20%) as well as in a replication
sample of childhood-onset schizophrenia. Schizophrenia
patients were over three times more likely to carry dele-
tions or duplications compared with controls. However,
there was no difference in the distribution of common
CNVs between cases and controls. The CNVs present in
schizophrenia patients were disproportionately more
likely to disrupt genes from signaling networks control-
ling neurodevelopment, including neuregulin and gluta-
mate pathways. Interestingly, similarly to Kirov et al,
105 a
deletion disrupting NRXN1 was found in identical twins
concordant for childhood-onset schizophrenia. ERBB4,
a type I transmembrane tyrosine kinase receptor for
neuregulin (NRG1), was also found to be disrupted by
a 399 kb deletion in one schizophrenia patient. Similarly,
a 503 kb deletion that disrupted SLC1A3, a glutamate
transporter was also observed. However, this excess of
rare CNVs was not replicated in an independent sample
of Han Chinese schizophrenia patients (155 cases and
187 controls).
109
Xu et al
106 analyzed the presence of de novo CNVs and
observed that these are approximately 8 times more fre-
quent in sporadic cases (10%, 15 of 152) than in controls
(1.3% (2 of 159). Furthermore, they did not observe any
de novo CNVs in familial cases (n=48). Additionally,
sporadic cases of schizophrenia were ~1.5-times more
likely to inherit a rare CNV (~30%, 46/152) than unaf-
fected controls (~20%, 32/159). Among the de novo
CNVs observed in cases, deletions were seen at 22q11.2
(1.8%) along with deletions at 12p11.23 and 16p12.1–
p12.2 which were also observed by Walsh et al.
112
The study by Stefansson et al
107 tested an interesting
hypothesis that regions in the genome that have a high
mutation rate, but harbor rare CNVs, are likely to be
selected against during evolution. These rare CNVs may
be associated with disorders such as schizophrenia,
autism, and mental retardation, which appear to reduce
fecundity of the affected patients. Using SNP arrays to
identify de novo rare CNVs in the healthy control pop-
ulation, they identified 66 de novo rare CNVs and tested
for association with schizophrenia in two independent
schizophrenia case-control samples (Phase I: 1433 cases
and 33 250 controls; Phase II: 3285 cases and 7951 con-
trols). They observed three deletions, 1q21.1, 15q11.2,
and 15q13.3, to be nominally associated with schizo-
phrenia and related psychosis in the Phase I samples. In
the phase II sample, all three deletions were significantly
associated with schizophrenia and related psychosis. In
the combined sample, the odds ratio (OR) varied from
14.8 for 1q21.1, 11.54 for 15q13.3 to 2.73 for 15q11.2. The
15q loci were not significant if patients with psychoses
other than schizophrenia were excluded. The 1q21.1
deletion which varies from 1.35Mb to 2.19Mb was pre-
sent in 0.23% (11 out of the 4718) of the cases compared
with 0.02% (8 of 41 199) controls. The 470 kb deletion
on 15q11.2 occurred in 0.55% of cases (26 of 4 718) ver-
sus 0.19% controls (79 of 41 194). The 15q13.3 deletion
spans 1.57Mb and is present in 0.17% of cases (7 of
4213) versus 0.02% of controls (8 of 39 800). They also
found the 22q11.2 deletion in 0.2% of the cases (8 of
3838). The association with 1q21.1 is interesting, as this
region has been associated with schizophrenia.
112 The
15q11.2 region has been associated with mental retar-
dation and is also deleted in a minority of cases with
Angelman syndrome or Prader–Willi syndrome. In the
15q13.3 deletion region, the alpha 7 subunit of the nico-
tinic receptor gene (CHRNA7) is present. This receptor
is targeted to axons by NRG1, and has been implicated
in schizophrenia and mental retardation.
107
In the study from the International Schizophrenia
Consortium,
108 a genome-wide survey of 3391 patients
with schizophrenia and in 3181 ancestrally matched con-
trols using SNP arrays revealed 6753 rare CNVs. These
rare CNVs, observed in less than 1% of the sample and
more than 100Kb in length, were 1.15-fold increased in
patients with schizophrenia in comparison with controls.
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2p16.3 (0.12%, NRXN1), 7q35 (0.09%, CNTNAP2),
12p11.23 (0.12%), 15q13.3 (0.03%, APBA2), 15q13.3
(0.27%, CHRNA7, OR=17.9), 16p12.2-12.1, (0.12%) and
22q11.2 (VCFS region, 0.38%, OR=21.6).
Further support for the role of rare CNVs in schizophre-
nia came from a recent study that analysed 471 patients
with schizophrenia or schizoaffective disorder and 2792
controls.
110 Kirov et al observed an excess of rare CNVs
larger than 1Mb in cases (OR=2.26, P=0.00027) compared
with controls. The associations were stronger with dele-
tions (OR=4.53, P=0.00013) than with duplications
(OR=1.71, P=0.04). Similar to the abovementioned stud-
ies, these investigators also observed deletion at 22q11.2
in two schizophrenia patients. A deletion at 17p12 was also
observed in two patients but not in controls. Unlike the
ISC study,
108 Kirov et al
110 did not observe an overall excess
burden of rare CNVs in their investigation. However, rare
CNVs >500kb were also enriched in schizophrenia cases
(OR=2.18). On combining their results with the ISC and
the SGENE study,
107 Kirov et al observed that the 17p12
deletion was more common in cases than controls
(OR~10, 0.15% vs 0.015%) and also observed the deletion
at 15q11.2 (OR=2.8, 0.62% vs 0.22). A duplication
observed at 16p13.1, which includes the DISC1 interact-
ing gene NDE1, was more common in cases than controls
in the Kirov study as well as the ISC study.
108
Need et al
100 in their GWAS investigation, analysed a
subset of patients for presence of copy number varia-
tions, and they identified large deletions (>2Mb) in eight
cases but not in controls. Of these four CNVs, one was
at 22q11.2, one at 16p13.11-p12.4 (includes the gene
NDE1 a binding partner for DISC1), one at 8p22 and
two at 1q21.1 (these are same as that reported by Stone
et al
108 and Stefansson et al
107). Overall, similarly to Kirov
et al,
110 they did not observe an excess of rare CNVs
(>100kb) in schizophrenia cases. Unlike Walsh et al
111
they did not observe an excess of rare CNVs disrupting
genes from the neurodevelopmental pathways. An
important difference may have been that the primary
investigation samples in the study by Walsh et al were
child-onset schizophrenia patients.
Similar observations have also been reported in Japanese
schizophrenic patients. Ikeda et al
113 did not observe an
excess of large rare CNVs (>500kb) in schizophrenia
patients, but observed an overall nonsignificant trend for
excess of rare CNVs in schizophrenia (P=0.087). Similar
to previous studies, they identified one deletion in a case
at 1q21.1, a deletion within NRXN1, and four duplica-
tions at 16p13.1 in cases, and one in a control subject.
However no deletions were observed at 22q11.2 or
15q13.3 loci. In a reverse trend for the 15q11.2 locus,
three deletions were observed in controls compared with
one in cases.
Based on all the above studies, we may summarize that
rare CNVs, until recently, were only thought to play an
important role in disorders such as mental retardation
and autism. However, it now appears that CNV make a
substantial contribution to the understanding of schizo-
phrenia etiology and pathogenesis. Deletions at 1q21.1,
15q11.2, and 15q13.3 might join the ranks of 22q11.2 as
uncommon but important chromosomal aberrations that
can lead to severe behavioral disturbances including
schizophrenia.
What next? Conclusions and future directions
Despite decades of research effort, our understanding of
the genesis of schizophrenia remains an enigma. The
methods used for mapping susceptibility genes have pro-
gressed enormously over the past several years. The
genome-wide studies have pointed to the role of both
common variants as well as rare variants in schizophre-
nia susceptibility. However, the effect size associated
with common variants is smaller than initially estimated
(OR<1.2) and only rare variants generally have a large
effect. Furthermore, the number of total susceptibility
variants for schizophrenia may be in the order of thou-
sands.
114 Considering the low effect size observed for the
associated SNPs the sample size required for replicating
these associations with adequate power would theoret-
ically be up to 100 000 each of cases and controls. To
achieve such sample sizes with detailed and consistent
phenotype measurement is a formidable challenge. It
may be that testing broader phenotypes such as psy-
chosis might help the field to collect these large numbers
as well as detect genes which overlap between different
disorders. However, the opposite approach may also be
valid, that is to narrow the phenotype to a hopefully
more homogeneous subgroup, for example including use
of brain imaging measures, electrophysiology, or care-
fully defined symptom subtypes. A smaller number of
genes of greater effect sizes may influence more refined,
specific phenotypes.
An interesting outcome of the GWAS data analyses is
that there appears to be a considerable overlap between
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idea that they exist on a clinical continuum with over-
lapping symptom dimensions. A recent study in two mil-
lion Swedish families also observed that schizophrenia
and bipolar disorder share susceptibility genes.
93
Furthermore, the GWAS study by O’Donovan et al
50
found that inclusion of patients with bipolar disorder
along with schizophrenia further strengthened their
association with the SNP rs1344706 in the ZNF804A
gene. The demonstration of a functional effect that alters
connectivity of brain structures associated with both
schizophrenia and bipolar disorder lends further sup-
port
94 to the overlap of the two diseases. Similarly, genes
such as DISC1,
115 NRG1,
116 and ANK3
100 are associated
with both schizophrenia and bipolar disorder. A similar
overlap may also exist with autism spectrum disorders
wherein deletions in the Neurexin 1 gene have been
associated with both autism and schizophrenia. One
implication of this high degree of overlap is that com-
bining phenotypes to build very large sample sizes may
be a useful strategy to find small effect genes. These
small effect genes may then be able to be assembled into
neurobiological systems that would explain a significant
degree of the pathological mechanisms of schizophrenia
as well as other behavioral disorders. 
Another complimentary strategy for detecting disease
associated genetic variants will be the use of endophe-
notypes. These can be defined as disease-associated phe-
notypes that are heritable, state independent, cosegre-
gate with illness in families, and are also found in
unaffected family members.
117 Generally the terms
“alternate phenotype” or “intermediate” means a phe-
notype that does not meet all of the criteria for an
endophenotype, but represents a different and usually
more objective measure of part of the schizophrenia
phenotype. One of the historically most studied
endophenotypes in schizophrenia is abnormal move-
ment of the eyes while tracking a moving object across
a screen.
118 Other endophenotypes include impairments
in attention, language, and memory (neurocognitive
deficits), deficits in sensory gating of auditory informa-
tion (prepulse inhibition),
119 P50 event-related poten-
tial,
120 P300 event-related potential
121 and structural imag-
ing phenotypes (for a detailed review see ref 122).
Interestingly, these endophenotypes are generally applic-
able to both schizophrenia and bipolar disorder, and sev-
eral genes have been reported to influence them. For
example the catechol-o-methyl transferase gene
(COMT) and Reelin are associated with neurocognitive
deficits, and the alpha 7 nicotinic receptor subunit gene
variants are associated with P50 deficits. Overall there is
hope that the use of endophenotypes will improve our
understanding of the biology of the disease as well as
creating phenotypically more homogeneous groups of
patients that can reduce the number of samples required
for detecting genetic signals.
The effect of environmental factors, including maternal
infection (serological evidence of influenza infection
during pregnancy), and recreational drug use/abuse
should also be taken into account when conducting asso-
ciation studies in schizophrenia.
123 Cannabis usage is an
important risk factor aggravating psychosis, and preon-
set cannabis use hastens the onset of prodromal symp-
toms as well as fully developed psychosis. These and
likely other environmental factors need to be considered
in the design of future genetic studies. Furthermore, epi-
genetic changes, including both DNA methylation and
histone acetylation, have also been suggested to play an
important role in development of major psychoses.
124,125
These epigenetic mechanisms can be influenced by envi-
ronmental effects such as stress (cortisol) and hormonal
factors. Thus we need a comprehensive systems biology
approach to incorporate the effect of genetic and non-
genetic factors to understand the genesis of schizophre-
nia and related disorders.
A possible approach that may take into account most of
these variables is high-throughput whole-genome
sequencing. Whole-genome sequencing has the poten-
tial to detect virtually all SNPs, CNVs (both large as well
as relatively small deletions <1kb) and epigenetic mod-
ifications (DNA methylation). Small deletions and dupli-
cations are relatively common in the human genome and
have been shown to affect levels of several brain
expressed genes (eg, DAT1, 5-HTTLPR). The cost of
high-throughput sequencing at present is rather expen-
sive but is comparable to the price of first-generation
SNP chips. Further technological advances and reduc-
tion in cost of high throughput sequencing will make the
discovery of each and every variant in a given person’s
genome feasible. While this more extensive and detailed
information on each subject’s DNA will provide com-
prehensive information at the DNA level, the data
analysis, multiple testing, and other bioinformatic chal-
lenges are also greatly increased.
At this juncture in the research effort, investigations of
schizophrenia have demonstrated that genetic factors
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However, to progress further we need better phenotypic
classification of our patients. A major area of develop-
ment in this regard is the steady advance of neuroimag-
ing technology. We now can have phenotypes of the vol-
ume of the dorsal lateral prefrontal cortex, or the
connectivity between different brain regions. It should
be the case that more accurate study of the target organ
in schizophrenia research, that is the brain, will lead to
more objective and reliable associations with genetic
variants. Also, the methods to capture the complete vari-
ability of the genome (as well as the epigenome) will add
to the comprehensiveness of the measurement of DNA-
based information. Furthermore, a concerted effort is
needed to understand the biology (the annotation) of
the disease-associated genes. These genes will help us in
identifying novel targets for drug development and
thereby improve the efficacy of the treatment. 
The discovery of genetic factors also leads to the consid-
eration of whether or not it is useful to perform genetic
testing in a clinical setting. In fact, there are direct-to-
consumer genetic testing services for schizophrenia
already available on the internet. Most regulatory author-
ities (for example see the International Society for
Psychiatric Genetics Web site: www.ispg.org) agree that
genetic testing for schizophrenia is premature at this
stage, given the small odds ratios and inconsistent repli-
cations reviewed above. Until some as-yet unknown
approach is achieved to combine large numbers of small
effect genes into meaningful prediction algorithms, we
are likely facing many more years of research before
acceptable testing for risk is possible. More hopefully, the
uncommon but large effect CNVs on 22q, 15q, 16p, and
1q, that appear to be replicating fairly well in large
datasets, may lead to tests that could identify molecular
subtypes for at least a small percentage of schizophrenia
cases. These molecular subtypes may in turn lead to bet-
ter understanding of the pathogenesis of schizophrenia,
and treatment might become more specific and individ-
ualized for these cases. Through the continued efforts of
careful investigation in genetics of schizophrenia that
embrace the nuances of phenotype and the latest tech-
nological developments, the field has an excellent chance
to solve the etiologic puzzle of this enigmatic disorder. ❏
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Genética en la esquizofrenia: 
¿dónde estamos y qué viene?
La comprensión de las bases genéticas de la esqui-
zofrenia sigue constituyendo un importante desa-
fío. La investigación realizada durante las últimas
dos décadas ha aportado algunos genes candidato
que desafortunadamente no han podido ser repli-
cados en forma consistente a través de o dentro de
una población. Los recientes estudios de asociación
del genoma completo (AGC) y los estudios de
variantes del número de copias (VNC) han aportado
evidencia importante que sugiere un papel de
numerosas VNC tanto comunes como raras en la
génesis de la esquizofrenia. La carga de las varian-
tes del número de copias raras parece estar aumen-
tada en los pacientes esquizofrénicos. Una obser-
vación constante en los estudios de AGC es la
asociación de la esquizofrenia con marcadores
genéticos que contienen loci para genes que inclu-
yen el NOTCH4 y la proteína histona en el complejo
mayor de histocompatibilidad (6p22.1). Los estudios
de genética molecular también están demostrando
que hay más sobreposición entre los genes de sus-
ceptibilidad para la esquizofrenia y el trastorno
bipolar de lo que se sospechaba previamente. En
esta revisión se resumen los principales hallazgos de
la última década y se sugieren áreas de investiga-
ción a futuro. 
Génétique dans la schizophrénie : 
où en sommes-nous et où va-t-on ?
Il est encore très difficile de comprendre les bases
génétiques de la schizophrénie. Ces vingt dernières
années, la recherche a fourni plusieurs gènes can-
didats qui n’ont malheureusement pas été répliqués
de façon régulière au sein ou à travers une popu-
lation. Les récentes études d’association du génome
entier (GWAS) et les études de variation du nombre
de copies (CNV) ont donné des preuves tangibles
d’un rôle de grands CNV  rares et communs dans la
genèse de la schizophrénie. Ainsi, la fréquence de
certains CNV rares semble augmentée chez les schi-
zophrènes. En outre, les études sur le génome
entier montrent de façon régulière une association
entre la schizophrénie et des marqueurs génétiques
des gènes contenant le complexe majeur d’histo-
compatibilité (6p22.1) y compris NOTCH4 et les loci
codant pour la protéine histone. Les études de
génétique moléculaire ont également démontré
qu’il y a plus de recoupements entre les gènes de
susceptibilité de la schizophrénie et la maladie
bipolaire qu’on ne le pensait auparavant. Nous
résumons dans cet article les principaux résultats
des 10 dernières années et proposons des pistes
pour la recherche future.
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